Johnson & Johnson on Oct. 19 reported lower-than-expected quarterly revenue after sales of the company’s Covid-19 vaccine missed Wall Street estimates following a string of production setbacks.
Outside advisers to the U.S. Food and Drug Administration on Oct. 15 unanimously recommended the regulatory agency authorize a second shot of Johnson & Johnson’s Covid-19 vaccine for all recipients of the one-dose inoculation.
Facing thousands of lawsuits related to Johnson & Johnson’s talc-based products, the life sciences giant is launching a separate subsidiary dubbed LTL Management LLC that will take the brunt of potential legal liabilities.
Bayer terminated a vaccine manufacturing partnership under which the company would have helped produce CureVac’s Covid-19 shot, a spokesperson for Bayer told a German newspaper.
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.
The Ashfield Excellence Academy was formed to design, develop and deliver specialist training, skills assessments and process consultancy to the healthcare and pharma industries.
Japan’s Takeda Pharmaceutical announced deals with two biotech companies, Seattle-based Immusoft and San Diego’s Poseida Therapeutics.
People who received Johnson & Johnson’s Covid-19 vaccine will have a stronger neutralizing antibody response if they get an mRNA shot as the second dose, Axios reported on Oct. 12, citing a person who has seen data collected by the U.S. National Institutes of Health (NIH).
Shares of GlaxoSmithKline climbed in trading on rumors that the consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
CureVac NV said on Oct. 12 the company will give up on the biotechnology firm’s first-generation Covid-19 vaccine candidate and instead focus on collaborating with GSK to develop improved mRNA vaccine technology.